Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 11;23(1):67.
doi: 10.1186/s10194-022-01431-x.

European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update

Simona Sacco  1 , Faisal Mohammad Amin  2   3 , Messoud Ashina  2 , Lars Bendtsen  2 , Christina I Deligianni  2 , Raquel Gil-Gouveia  4   5 , Zaza Katsarava  6   7 , Antoinette MaassenVanDenBrink  8 , Paolo Martelletti  9 , Dimos-Dimitrios Mitsikostas  10 , Raffaele Ornello  11 , Uwe Reuter  12   13 , Margarita Sanchez-Del-Rio  14 , Alexandra J Sinclair  15   16 , Gisela Terwindt  17 , Derya Uluduz  18 , Jan Versijpt  19 , Christian Lampl  20
Affiliations

European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update

Simona Sacco et al. J Headache Pain. .

Abstract

Background: A previous European Headache Federation (EHF) guideline addressed the use of monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway to prevent migraine. Since then, randomized controlled trials (RCTs) and real-world evidence have expanded the evidence and knowledge for those treatments. Therefore, the EHF panel decided to provide an updated guideline on the use of those treatments.

Methods: The guideline was developed following the Grading of Recommendation, Assessment, Development, and Evaluation (GRADE) approach. The working group identified relevant questions, performed a systematic review and an analysis of the literature, assessed the quality of the available evidence, and wrote recommendations. Where the GRADE approach was not applicable, expert opinion was provided.

Results: We found moderate to high quality of evidence to recommend eptinezumab, erenumab, fremanezumab, and galcanezumab in individuals with episodic and chronic migraine. For several important clinical questions, we found not enough evidence to provide evidence-based recommendations and guidance relied on experts' opinion. Nevertheless, we provided updated suggestions regarding the long-term management of those treatments and their place with respect to the other migraine preventatives.

Conclusion: Monoclonal antibodies targeting the CGRP pathway are recommended for migraine prevention as they are effective and safe also in the long-term.

Keywords: Calcitonin gene-related pathway; Guideline; Migraine; Monoclonal antibodies; Prevention.

PubMed Disclaimer

Conflict of interest statement

Competing interests are reported in Supplemental File S1.

Figures

Fig. 1
Fig. 1
PRISMA Flowchart of study selection
Fig. 2
Fig. 2
Risk of bias summary for each included study
Fig. 3
Fig. 3
Forest plots of comparison: 1 Monoclonal antibodies vs placebo - Episodic migraine
Fig. 4
Fig. 4
Forest plots of comparison: 2 Monoclonal antibodies vs placebo - Chronic migraine
See this image and copyright information in PMC

References

    1. Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20(1):6. doi: 10.1186/s10194-018-0955-y. - DOI - PMC - PubMed
    1. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. doi: 10.1136/bmj.b2535. - DOI - PMC - PubMed
    1. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71. - DOI - PMC - PubMed
    1. The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system. Available from: http://gdt.guidelinedevelopment.org/app/handbook/handbook.html. Accessed 15 Feb 2022.
    1. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias) J Clin Epidemiol. 2011;64(4):407–415. doi: 10.1016/j.jclinepi.2010.07.017. - DOI - PubMed

Publication types

MeSH terms

Substances